Company Overview and News

8
Eventbrite: Does It Have A Bright Enough Future For Investors?

2018-10-03 seekingalpha - 2
This is not a software company - it is a ticket vendor who uses some technology.
EB PSTG P

3
Bulletproof Investing Performance Update: Week 43

2018-09-25 seekingalpha - 1
It has been 6 months since I presented four hedged portfolios and 10 top names in week 43 of my Marketplace service (March 22). Here's how everything did.
ODFL BURL PSTG GMED NFLX CHE RHT TWLO HLF CCMP GWW EPAM NSP ODLF

1
Why Is Pure Storage (PSTG) Up 10.7% Since Last Earnings Report?

2018-09-20 zacks - 1
A month has gone by since the last earnings report for Pure Storage (PSTG - Free Report) . Shares have added about 10.7% in that time frame, outperforming the S&P 500.
PSTG HPE

5
Is This The Next Big Thing In Retail?

2018-09-18 oilprice - 1
Your license and viewing of our content is subject to the disclosures contained after this article.
SHOP PSTG AWSM VEEV AAPL CLS BB BBRY

8
With tobacco revenue now forbidden, F1 turns to high-tech

2018-09-15 livemint
For decades, Formula One was synonymous with tobacco. Not only was the sport awash with money from cigarette companies, but the cars’ liveries were also reflections of their sponsors, from the red and white Marlboro McLarens to the black and gold of the John Player Special Lotus.
PM PSTG BATS 4162

 
PSTG / Pure Storage, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-09-10 sec.gov
SCHEDULE 13G Amendment No. 6 PURE STORAGE INC CLASS A COMMON STOCK Cusip #74624M102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #74624M102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,775,668 Item 6: 0 Item 7: 17,837,447 Item 8: 0 Item 9: 17,837,447 Item 11: 10.
PSTG

 
PSTG / Pure Storage, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-09-10 sec.gov
SCHEDULE 13G Amendment No. 6 PURE STORAGE INC CLASS A COMMON STOCK Cusip #74624M102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #74624M102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,775,668 Item 6: 0 Item 7: 17,837,447 Item 8: 0 Item 9: 17,837,447 Item 11: 10.
PSTG

161
Tracking Chase Coleman's Tiger Global Portfolio - Q2 2018 Update

2018-09-05 seekingalpha - 9
The largest three positions are Spotify, Amazon.com, and JD.com, and they add up to ~30% of the portfolio.
RDFN BCS NOW HUYA REDU FPI CRM QSR.WI SOGO 83SF FEYE AMZN 83SK TWTR MELI SWCH TEAM PSTG COUP BILI CLDR MSFT JD FB FIT LC MDB DOCU NFLX APO ADBE DESP DBX OKTA QSR 47MC SHOP NETS TDG RUN ZTO MA PVTL AVLR V BKNG IQ ADSK FLT

2
PSTG / Pure Storage, Inc. 10-Q (Quarterly Report)

2018-09-04 sec.gov - 2
Document UNITED STATES
PSTG

9
Do Options Traders Know Something About Pure Storage (PSTG) Stock We Don't?

2018-09-04 zacks
Investors in Pure Storage, Inc. (PSTG - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 7, 2018 $10.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
TSNU PSTG TSN ADBE

 
Nutanix, Inc.'s (NTNX) CEO Dheeraj Pandey on Q4 2018 Results - Earnings Call Transcript

2018-08-31 seekingalpha
Good afternoon. My name is Mike and I will be your conference operator today. At this time, I would like to welcome everyone to the Nutanix Fourth Quarter and Fiscal 2018 Financial Results Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]
ISCA ISCB PSTG NTNX RHT

28
Jeff Reeves's Strength in Numbers: Stocks in these 5 tech hardware companies should keep flying high

2018-08-28 marketwatch
Most tech investors are following some flashy trends right now, from the boom in cybersecurity spending to the megatrend of cloud computing to emerging intelligence technologies.
PSTG MU AMD NVDA INTC

1
Pure Storage (PSTG) Hits a Fresh 52-Week High on Upbeat Q2

2018-08-24 zacks
Shares of Pure Storage, Inc. (PSTG - Free Report) scaled a 52-week high of $26.76, eventually closing marginally lower at $26.52 on Aug 23. The company has a market capital of $5.81 billion. The stock was up 5.5% in yesterday’s trading session. The rally can be attributed to the company’s impressive fiscal second-quarter 2019 results. Furthermore, the investors seem to be optimistic about the company’s first-ever buyout of StorReduce.
PSTG AZPN PAYC

12
Pure Storage (PSTG) Looks Good: Stock Adds 5.5% in Session

2018-08-24 zacks
Pure Storage, Inc. (PSTG - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $21.66 to $25.15 in the past one-month time frame.
NWL PSTG NTAP

8
Top Stock Reports for Medtronic, EOG Resources & CSX Corporation

2018-08-23 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Medtronic (MDT), EOG Resources (EOG) and CSX Corp. (CSX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
SOJA STZ.B SO TXN CNX.WI PSTG STZ MDT EOG ALL ADI CSX ADSK LVS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 74624M102